CLINICAL TRIAL SUMMARY

MDACC Study No:2011-0857 (clinicaltrials.gov NCT No: NCT01437787)
Title:A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study of SAR302503 in Patients with Intermediate-2 or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis with Splenomegaly
Principal Investigator:Jorge Cortes
Treatment Agent:SAR302503
Study Status:Closed
Study Description:You are currently taking part in the 2011-0857 research study. The purpose of
this form is to tell you about new information about the study drug that
affects your participation in this study.

Hide details for General InformationGeneral Information

Disease Group:Myeloproliferative Diseases
Phase of Study:Phase III
Treatment Agents:SAR302503
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Sanofi US
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
Dept:Leukemia
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults